Impact of Clinical Factors and Treatments on SMARCB1 (INI‐1)‐Deficient Sinonasal Carcinoma

The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI‐1)‐deficient sinonasal carcinoma. Patients were treated from 2014 to 2021 and followed for a median of 22.3 months. The median overall survival (OS) and disease‐free survival (DFS) were 31.8 and 9.9 mont...

Full description

Saved in:
Bibliographic Details
Published in:Otolaryngology-head and neck surgery 2023-08, Vol.169 (2), p.435-440
Main Authors: Contrera, Kevin J., Shakibai, Nasim, Su, Shirley Y., Gule‐Monroe, Maria K., Roberts, Dianna, Brahimaj, Bledi, Williams, Michelle D., Ferrarotto, Renata, Phan, Jack, Gunn, Brandon, Raza, Shaan, DeMonte, Franco, Hanna, Ehab Y.
Format: Article
Language:English
Subjects:
carcinoma
Carcinoma - genetics
Carcinoma - pathology
Carcinoma - therapy
Humans
induction chemotherapy
INI‐1
Maxillary Sinus Neoplasms - genetics
Maxillary Sinus Neoplasms - pathology
Maxillary Sinus Neoplasms - therapy
Paranasal Sinus Neoplasms - genetics
Paranasal Sinus Neoplasms - pathology
Paranasal Sinus Neoplasms - therapy
sinonasal
SMARCB1
SMARCB1 Protein - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to report outcomes for 19 consecutive patients with SMARCB1 (INI‐1)‐deficient sinonasal carcinoma. Patients were treated from 2014 to 2021 and followed for a median of 22.3 months. The median overall survival (OS) and disease‐free survival (DFS) were 31.8 and 9.9 months, respectively. Patients with nasal cavity or maxillary sinus tumors had 84% better disease‐specific survival (DSS) (hazard ratio [HR], 0.136; 95% confidence interval [CI], 0.028‐0.66; p = .005) and 71% better DFS (HR, 0.29; 95% CI, 0.097‐0.84; p = .041) than patients with other sinonasal sites. Patients who received induction chemotherapy were 76% less likely to die of disease (DSS HR, 0.241; 95% CI, 0.058‐1.00; p = .047). In the largest single‐institution study of SMARCB1‐deficient sinonasal carcinoma to date, OS and DFS approached 3 years and 1 year, respectively, but were better for nasal cavity and maxillary sinus tumors. Patients may benefit from induction chemotherapy.
ISSN:0194-5998
1097-6817
DOI:10.1002/ohn.310